HCPCS code Q4143: Repriza billing, coverage and fee schedule

Key takeaways

HCPCS code Q4143 describes Repriza, a human allograft skin substitute reported per square centimeter of wound surface area.

Coverage is governed by a Local Coverage Determination (LCD) for bioengineered skin substitutes applied to lower extremity chronic non-healing wounds.

Units must be calculated precisely. The number of square centimeters of wound surface area determines how many units to report.

From January 1, 2026, Medicare pays Q4143 as an incident-to supply at a single national rate of about $127.14 per sq cm. The high-cost and low-cost tiers are gone.

Skin substitute claims use modifier JC when the product is applied as a graft, and JD when it is not.

Pabau’s claims management software helps wound care practices track unit calculations, attach supporting documentation, and submit Q4143 claims accurately.

HCPCS code Q4143 reports Repriza, a human allograft skin substitute, and it is billed per square centimeter of wound surface area. It sits in the Q4101-Q4440 range of CMS-maintained HCPCS Level II codes covering skin substitutes and biologicals. From January 1, 2026, CMS pays for the product as an incident-to supply at a single national rate. The high-cost and low-cost tiers that set the rate through 2025 no longer apply.

Coverage is decided by the Medicare Administrative Contractor for your jurisdiction, so a claim paid in one state can be denied in another. Unit reporting is the other common failure point. Wound care billing software that keeps the measurement and the claim line in one record makes a mismatch easy to catch before submission.

Repriza: product overview and clinical application

Repriza is a human allograft skin product from Promethean LifeSciences, used in the management of chronic, non-healing wounds on the lower extremities. It works as a wound covering that supports tissue regeneration by giving cells a scaffold to grow into. That makes it distinct from a simple wound dressing.

CMS recognizes Repriza as a skin substitute product within the Q-code range. It therefore falls under the same LCD framework that governs bioengineered and allograft skin substitutes applied to lower extremity wounds. That classification sets which diagnoses are covered. It also puts the product inside the single national payment rate CMS introduced for CY2026.

• Product type: Human allograft skin substitute (non-sheet classification under Palmetto GBA guidance)
• Intended wound types: Diabetic foot ulcers, venous leg ulcers, and other lower extremity chronic non-healing wounds
• Billing unit: Per square centimeter of wound surface area actually covered by the product
• Regulatory pathway: A human cells, tissues, and cellular and tissue-based product (HCT/P). It is self-determined under Section 361 of the Public Health Service Act, not licensed as a biologic under Section 351
• Why the pathway matters: Section 361 HCT/Ps fall inside the CY2026 flat rate for skin substitutes, while Section 351 licensed biologics keep ASP-based pricing

Q4143 Medicare coverage criteria and LCD requirements

Coverage for HCPCS code Q4143 is governed by the Local Coverage Determination for bioengineered skin substitutes applied to lower extremity chronic non-healing wounds. Each Medicare Administrative Contractor (MAC) administers that LCD for its own jurisdiction. Palmetto GBA has published detailed guidance on non-sheet skin substitute billing that applies to Q4143.

Coverage is not automatic. The LCD sets conditions that must all be met before a Q4143 claim will be covered. A claim that misses one criterion faces denial, however appropriate the treatment was clinically.

• The wound must be a chronic, non-healing lower extremity wound (typically defined as not healing despite 30 days of standard wound care)
• The patient must have received appropriate standard wound care before application of the skin substitute
• The treating clinician must document wound dimensions, wound type, and duration of non-healing
• The product must be applied in a covered place of service (office, outpatient department, or ambulatory surgical center in most LCDs)
• The claim must be supported by covered ICD-10 diagnosis codes specified in the applicable LCD
• Prior authorization may be required, depending on the MAC jurisdiction and the payer. Confirm the requirement before scheduling treatment

ICD-10 codes that support Q4143 claims

Only ICD-10 diagnosis codes explicitly listed in the governing LCD are covered for Q4143. A claim submitted with a non-covered diagnosis is one of the most common denial triggers. The table below shows the categories of diagnoses covered under the standard skin substitute LCD for lower extremity wounds.

Covered ICD-10 codes are LCD-specific and subject to revision. List only codes confirmed in the active CMS coverage article for your MAC jurisdiction. Do not infer coverage from adjacent wound care codes that the LCD does not name.

CPT codes paired with HCPCS code Q4143

HCPCS code Q4143 reports the product itself, not the application procedure. A wound care practice must bill a separate CPT application code on the same claim to report the work of applying the skin substitute. The CPT code and Q4143 are submitted together.

For a lower extremity wound with a total surface area under 100 sq cm, CPT 15271 is the base code. CPT 15272 is added for each additional 25 sq cm beyond the first 25.

The pair changes once the total wound surface area reaches 100 sq cm. CPT 15273 replaces 15271 for the first 100 sq cm, and CPT 15274 replaces 15272 for each additional 100 sq cm. The face, scalp, hands and feet group follows the same pattern, where 15277 and 15278 take over from 15275 and 15276 at the same threshold.

The low-cost application codes C5271 through C5278 were deleted on December 31, 2025. CPT 15271 through 15278 now cover every skin substitute application, in every setting. Report Q4143 units alongside the CPT code, reflecting the total wound surface area covered by Repriza. The panel below sets out the three decisions a single Q4143 claim line depends on.

Medicare fee schedule for HCPCS code Q4143 in 2026

Medicare pays about $127.14 per square centimeter for Q4143 in CY2026, and that single national rate applies wherever the product is applied. CMS published the figure as $127.28 in the final rule, then corrected it to $127.14 on November 26, 2025.

The change came from the CY2026 Medicare Physician Fee Schedule final rule (CMS-1832-F, published November 5, 2025) and the companion OPPS final rule. Both reclassified skin substitutes as incident-to supplies, bundled into the covered CPT application procedure. Product-specific ASP pricing and the high-cost versus low-cost tier system were not revised. They were abolished from January 1, 2026.

Setting no longer changes the amount paid for the product, only who receives it. In the physician office, the practice is paid the flat per sq cm amount alongside the application code. In a hospital outpatient department or ASC, that payment sits inside the facility’s payment for the procedure. The practitioner bills no separate product line at all.

The flat rate covers all three FDA pathways CMS grouped together: PMA products, 510(k) and De Novo products, and self-determined 361 HCT/Ps. Only skin substitutes licensed as biologics under Section 351 of the Public Health Service Act stay on ASP-based pricing. Repriza is a 361 HCT/P, so Q4143 is priced at the flat rate rather than product by product.

Use the CMS Physician Fee Schedule lookup tool to confirm the amount loaded for the year you are billing. Any figure from a fee schedule aggregator needs checking against the CMS published schedule or your MAC’s pricing file. Many aggregators still carry pre-2026 tier pricing.

Check the remittance advice once each payment posts. Compare the paid amount against the national per sq cm rate multiplied by the units you reported. Query any difference while the claim is still recent.

How to bill Q4143: Step-by-step billing workflow

Billing HCPCS code Q4143 correctly takes attention at each step of claim preparation. Missing any one step is enough to generate a denial. Follow these steps for every Q4143 claim.

1. Measure the wound surface area. Record wound length and width in centimeters at the time of application. Multiply length by width to calculate the surface area covered. This figure determines the number of Q4143 units to report.
2. Select the correct place of service code. Office (POS 11), hospital outpatient (POS 22), and ambulatory surgical center (POS 24) are the settings most LCDs cover. The place of service section below explains who is paid for the product in each one.
3. Pair the CPT application code. Add CPT 15271 as the primary procedure code for a lower extremity wound under 100 sq cm. Add CPT 15272 for each additional 25 sq cm. At 100 sq cm or more, use CPT 15273 and 15274 instead. Q4143 and the CPT code must appear on the same claim.
4. Apply the correct modifiers. Skin substitute claims use JC when the product is applied as a graft, and JD when it is not. The modifiers section below covers those and the others your MAC may require.
5. Attach the covered ICD-10 diagnosis code. The diagnosis must be listed as a covered code in the active LCD for your MAC.
6. Verify prior authorization if required. Some MAC jurisdictions and commercial payers require pre-authorization for skin substitute applications. Confirm requirements before the procedure date.
7. Submit a clean claim. Every field must be complete, and the documentation section below lists the supporting records to have on file. A claim that goes out complete the first time avoids the cost of rework.

Modifiers used with Q4143

JC and JD are the modifiers specific to skin substitutes, per CMS and Palmetto GBA guidance. Neither one describes wound size. Confirm which of them your MAC expects on a Q4143 line.

Place of service requirements

Place of service decides whether the claim is covered, and which party is paid for the product. Most LCDs for skin substitutes cover application in offices (POS 11), hospital outpatient departments (POS 22), and ambulatory surgical centers (POS 24). Inpatient hospital settings (POS 21) are typically excluded. Since January 1, 2026 the per sq cm product rate is identical across the covered settings, so only the billing party changes. Confirm covered POS codes in your MAC’s active LCD before billing.

Documentation requirements for Q4143 claims

Inadequate documentation is a frequent reason Q4143 claims are denied. The LCD specifies what must be in the medical record, and MAC auditors check for each element. A standardized wound care record template reduces audit risk, and building the LCD’s requirements into it from the start avoids retroactive repayments.

• Wound measurement record: Length, width, and calculated area in sq cm recorded at the date of service; must match the units reported on the claim
• Wound type and diagnosis: Clear documentation of the wound etiology (diabetic, venous, and so on) matching the submitted ICD-10 code
• Duration of non-healing: Evidence that the wound has been present and non-healing for the required period (typically 30 days of standard care)
• Prior treatment record: Documentation of standard wound care provided before skin substitute application, as required by the LCD
• Product application record: Name of the product applied (Repriza), lot number if available, and method of application
• Signed ABN (if applicable): If coverage is not expected, an Advance Beneficiary Notice of Noncoverage must be on file before the procedure
• Prior authorization documentation: If PA was obtained, include the authorization number on the claim

A charge sheet that captures each of these elements at the point of care keeps the record complete. Build the wound measurement and product fields into your visit note template, so staff finish them before the patient leaves.

CMS policy updates affecting Q4143

The CY2026 Medicare Physician Fee Schedule final rule rewrote how every Q-range skin substitute is paid, Q4143 included. CMS did not adjust the high-cost and low-cost thresholds. It removed the tier system altogether, effective January 1, 2026.

• Tier system abolished: CMS-1832-F, published November 5, 2025, ended the high-cost and low-cost split for skin substitutes. From January 1, 2026 the product is paid as an incident-to supply at one national rate, whichever tier it sat in before.
• One rate across settings: The companion OPPS final rule aligned hospital outpatient and ASC payment with the office rate. The product no longer carries a facility versus non-facility differential.
• Application codes consolidated: The low-cost application codes C5271 through C5278 were deleted on December 31, 2025. CPT 15271 through 15278 now apply to every product in every setting.
• Pricing exception for licensed biologics: Products licensed under Section 351 of the PHS Act keep ASP-based pricing. Repriza is a self-determined 361 HCT/P, so Q4143 sits inside the flat rate.
• New and discontinued codes: Q codes for skin substitutes are added and retired each quarter. Verify that Q4143 remains active, and that no successor code has been issued for Repriza in the current code year.
• Updated LCD policies: MACs have been revising their skin substitute LCDs to match the 2026 payment policy. Check the effective date on your MAC’s active LCD before billing.
• Frequency limitations: Several LCDs cap how many applications a single wound may receive. Confirm the limit that applies to your course of treatment.

The AAPC’s HCPCS code lookup database publishes quarterly updates on Q-code status changes, including effective and termination dates. Cross-reference it against your MAC’s published coverage articles before you bill Q4143.

Common billing errors with Q4143 and how to avoid them

Most Q4143 denials are preventable. These are the errors billing teams encounter most consistently, and each one has a straightforward fix.

• Wrong unit count: Reporting units based on the graft size available rather than the wound surface area actually covered. Units must reflect the wound, not the product packaging.
• Missing or wrong modifier: Omitting JC or JD, or reporting JC when the product was not applied as a graft. The modifier must match how the product was used, as documented in the chart.
• Non-covered ICD-10 code: Using a diagnosis code not listed in the active LCD for your MAC. Even where the wound is documented, an unlisted ICD-10 generates a denial. Map diagnoses to the LCD code list before every claim.
• Insufficient prior treatment documentation: Submitting without evidence that standard wound care was provided before the skin substitute application. The LCD requires this chronological record.
• Wrong CPT code: Billing 15271 for a wound whose total area is 100 sq cm or more, where 15273 is the base code. Site matters too, since the face, hands and feet group uses 15275 through 15278.
• No advance beneficiary notice when needed: Applying Repriza to a wound that falls outside the LCD without a signed ABN creates liability exposure. Where coverage is uncertain, get the ABN signed before treatment.
• Stale 2025 pricing logic: Posting an expected payment based on a tier price for a 2026 date of service. Billing a deleted C5271 through C5278 application code does the same. Both produce a variance that looks like a payer error.

Track skin substitute denials by reason code, and the pattern shows which error is driving them. Denial management processes then feed that finding back into the pre-submission checklist, so the same claim does not fail twice.

Related HCPCS skin substitute codes

Q4143 belongs to the Q4101-Q4440 skin substitute code family. The table below lists the codes closest to it, all billed per square centimeter. Our HCPCS code library carries the wider reference set for the Q range and the rest of HCPCS Level II.

How Pabau keeps Q4143 units tied to the wound record

In most wound care practices the measurement is charted in the clinical note, then the unit count is typed again into the billing system. The two records sit apart, so nobody catches the moment 18 sq cm in the chart becomes 20 units on the claim.

Pabau, our all-in-one practice management system, keeps the treatment note, the wound photos, and the invoice in one patient record. The measurement your clinician charts at the application visit sits beside the line you bill. A coder can check one against the other before the claim leaves the practice.

Supporting records stay attached to the same file, so the prior treatment history and the signed ABN are ready when a MAC asks for them. Reporting then shows which denial reason codes repeat across your skin substitute claims, which tells you where to fix the workflow first.

Struggling to track wound measurements and billing units across multiple claims?

Pabau’s claims management software lets wound care practices attach wound measurements, product details, and supporting records to each claim. That reduces Q4143 denials caused by missing or mismatched documentation.

Book a demo

Conclusion

Accurate Q4143 billing comes down to three habits. Record the wound in square centimeters and report units that match it. Pull the diagnosis from the active LCD’s covered list. Complete the documentation before the claim goes out. When one of those slips, the denial follows and the rework cost lands on the practice.

The payment side got simpler in 2026, because one national per sq cm rate now applies wherever Repriza is applied. The modifier is still worth a second look on every claim. JC and JD describe how the product was used, never how big the wound was. Get that pairing right and the remaining variable is your MAC’s coverage article, which is the one thing to check before each application. Book a demo to see how Pabau keeps wound measurements, documentation and Q4143 claim lines in one record.

Continue your research

Need guidance on medical billing compliance requirements? Medical billing compliance covers the documentation and audit standards that apply to wound care and skin substitute claims.

Want to understand how claims move through the payer system? Revenue cycle management explained walks through each stage from coding to payment posting.

Looking for a denial prevention framework? Denial management in healthcare covers root cause analysis and systematic approaches to reducing claim rejections.

Frequently asked questions